Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

The acidity may also trigger symptoms in people with interstitial cystitis, which causes pain and a feeling of pressure around the bladder. Additionally, juice contains a lot of sugar, which can ...

But few of us think about how what we eat and drink impacts our bladders. Although there’s no dietary ‘cure’ for a weak or irritated bladder, eating food and drink that support your urinary health – ...

Neoadjuvant mitomycin C before transurethral resection of bladder tumor (TURBT) showed a favorable safety profile in patients with non-muscle invasive bladder cancer (NMIBC). While an improvement in ...

Keeping its bladder clean, dry and mold-free between uses! That's where the DRYE device comes in, as it's a battery-powered fan designed specifically to dry hydration pack bladders. SUBSCRIBE ...

UGN-102 (intravesical mitomycin) induced a clinically meaningful complete response (CR) rate combined with acceptable tolerability among patients with recurrent low-grade intermediate-risk non-muscle ...

If you have bladder cancer, there are several treatment options. Your doctor will help you decide which one is best for you. Choosing the best treatment depends on a number of things ...

If a person frequently needs to pee but little comes out when they try to go, it can be due to a urinary tract infection (UTI), pregnancy, an overactive bladder, or an enlarged prostate.

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, ...

UGN-102 is UroGen’s sustained-release formulation of mitomycin, being developed for recurrent low-grade, intermediate-risk, non-muscle-invasive bladder cancer (LG-IR-NMIBC). Among the 41 ...

“Complication rates were super low: just 3.7% for prostate surgeries, 1.9% for kidney surgeries, and 17.9% for bladder surgeries, all beating safety goals from years of research”. The company further ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...